Overview

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Androgens
Diphosphonates
Zoledronic Acid